Soumendu Patra | Cancer biology | Best Researcher Award

Posted on by ScienceFather

Mr. Soumendu Patra – Cancer biology – Best Researcher Award

Alignment with Award Category

Soumendu Patra’s achievements align with categories recognizing excellence in scientific research, innovation, and academic contributions. His expertise in biosensor technology, molecular biology, and microbiology, coupled with his impactful research projects and publications, make him a strong contender for awards in microbiological research, biomedical innovation, and environmental biotechnology.

 

Raiganj University | India

Profile

Orcid

Scopus

🎓Early Academic Pursuits 

Education and Training

Soumendu Patra’s academic journey is marked by a strong foundation in microbiology. His pursuit of higher education began with a Bachelor of Science (B.Sc.) in Microbiology from Midnapore College (Autonomous), affiliated with Vidyasagar University, India, where he graduated in July 2019. Demonstrating his commitment to the field, he furthered his education by obtaining a Master of Science (M.Sc.) in Microbiology from West Bengal State University in 2021, achieving an impressive CGPA of 9.31/10. His academic excellence and dedication to microbiological research paved the way for his current Ph.D. studies at Raiganj University, where he is focused on biosensor technology for detecting HPV-associated cervical cancer.

💼Professional Endeavors 

Academic Positions

Soumendu Patra has gained substantial research experience throughout his academic career. Currently, he is a Research Scholar in the Department of Microbiology at Raiganj University, working on a thesis titled “Polydiacetylene-Liposome Based Biosensor for Rapid Detection in HPV-Associated Cervical Cancer.” Prior to this, he contributed significantly as a Project Assistant in a research project funded by the Department of Biotechnology, Government of India, focused on developing an early screening kit for HPV-associated cervical cancer.

📚Contributions and Research Focus on Cancer biology

Soumendu Patra’s research primarily revolves around microbiology, molecular biology, and biosensor technology. His ongoing Ph.D. research aims to develop a polydiacetylene-liposome-based biosensor for detecting HPV-associated cervical cancer, a project with immense implications for early cancer diagnosis.

Additionally, his research projects include:

  • HPV-Associated Cervical Cancer Early Screening Kit Development – This project involves screening and confirming cervical cancer patients through urine and vaginal swab sample collection, ELISA testing, sensor fabrication, and validation.
  • Anti-cancerous Flavonoids as Potential Inhibitors for Dengue Virus Replication – An in-silico study analyzing the interaction between anticancer flavonoids and dengue virus proteins using molecular docking and molecular dynamics simulations.
  • Isolation and Characterization of Multi-Metal Resistant Bacteria from Wastewater – A study on screening heavy metal-resistant bacteria for potential use in bioremediation.

🏆Accolades and Recognition 

Soumendu Patra has gained recognition through his participation in numerous conferences, workshops, and training sessions. Notable among these are: A poster presentation on “Coronavirus: Myths and Facts” at the UGC-SAP (DRS-II) Sponsored National Conference at Kalyani University. Participation in the UGC-sponsored National Seminar on “Role of Microbes for Sustainable Agriculture and Environment.” Training on metagenomics conducted by the Department of Microbiology at West Bengal State University in collaboration with IIT Madras.

🌍 Impact and Influence 

Community Impact

Soumendu Patra’s research has the potential to revolutionize early disease detection and environmental sustainability. His work on biosensors for HPV detection can significantly enhance cancer diagnosis, improving patient outcomes. Similarly, his contributions to microbial bioremediation can pave the way for innovative environmental cleanup strategies. His collaborations with esteemed researchers and institutions further amplify the impact of his work on global scientific advancements.

🔮Legacy and Future Contributions 

As a dedicated researcher, Soumendu Patra’s legacy will be shaped by his continued efforts in microbiology and biosensor technology. His work promises advancements in medical diagnostics and environmental biotechnology. He aspires to contribute to academia and industry by developing novel diagnostic tools and sustainable microbial applications, fostering scientific progress and public health improvements.

Conclusion

Soumendu Patra’s academic and research trajectory reflects his dedication to scientific excellence. From his foundational education in microbiology to his pioneering research in biosensors and microbial bioremediation, he has consistently demonstrated a commitment to advancing knowledge and solving real-world problems. His contributions to HPV detection and environmental sustainability position him as a promising researcher whose work will leave a lasting impact on both medical and environmental sciences.

📚Publications

HPV and Male Cancer: Pathogenesis, Prevention and Impact
Authors: Soumendu Patra; Harshita Shand; Sayan Ghosal; Suvankar Ghorai

Journals: Journal of the Oman Medical Association

Fatty acid binding protein as a new age biomarker

Authors: Harshita Shand; Soumendu Patra; Suvankar Ghorai

Journals: Clinica Chimica Acta

Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems

Authors: Ghorai, Suvankar; Shand, Harshita; Patra, Soumendu; Panda, Kingshuk; Santiago, Maria J.; Rahman, Md. Sohanur; Chinnapaiyan, Srinivasan; Unwalla, Hoshang J.

Journals: Pharmaceutics

Plant response–driven fertilizer nutrient development

Authors: Harshita Shand; Rittick Mondal; Pankaj Mandal; Soumendu Patra; Suvankar Ghorai; Amit Kumar Mandal

Journals: Essential Minerals in Plant-Soil Systems

 

Nathalie | Cancer research | Women Researcher Award

Posted on by ScienceFather

Dr. Nathalie – Cancer research – Women Researcher Award

Alignment with Award Category

Dr. Mazure’s groundbreaking research in cancer biology, particularly her work on metabolic shifts in cancer cells and the molecular mechanisms of cell death resistance, aligns perfectly with the award category recognizing excellence in scientific research in the field of cancer biology. Her contributions to understanding cancer metabolism, hypoxia, and the role of primary cilia in tumor survival have had far-reaching implications for cancer treatment and drug development.

 

CNRS | France

Profile
orcid

🎓Early Academic Pursuits 

Education and Training

Nathalie Mazure was born on July 8, 1966, in Issy-les-Moulineaux, France. Her academic journey began with a strong foundation in biological sciences. She earned her PhD in 1994 from the University of Technology of Compiègne, focusing on microbial genetics. This early research sparked her passion for exploring the molecular mechanisms underlying cellular functions, which would later become the central theme of her academic and professional pursuits.

💼Professional Endeavors 

Academic Positions

Dr. Mazure’s career spans multiple academic and research positions, primarily centered around cancer research, molecular biology, and cellular metabolism. Since January 2024, she has been co-directing Team 5 “Cancer, Metabolism and Microenvironment” at the Institut C3M (INSERM U1065) and the University of Nice-Sophia Antipolis. Her research theme focuses on critical areas such as cancer, cell death resistance, hypoxia, and the role of VDAC1 and primary cilium in these processes.

📚Contributions and Research Focus on Cancer research

Dr. Mazure’s research has been pivotal in exploring the molecular mechanisms involved in cancer progression, particularly in how tumor cells survive in low-oxygen (hypoxic) environments. Her work on VDAC1, a mitochondrial protein, has led to significant insights into cell death resistance in cancer cells. The development of a predictive biomarker for chemoresistance, based on the molecular interactions between VDAC1 and other cellular components, is one of her notable contributions. In addition to her work on cancer cell metabolism, Dr. Mazure has been a key figure in advancing our understanding of primary cilium function in cancer cells. This organelle, often overlooked in traditional cancer research, plays a critical role in cellular signaling pathways that regulate cell growth and survival. Her interdisciplinary approach, combining cell biology, molecular genetics, and cancer research, has led to a deeper understanding of the metabolic shifts that occur in cancer cells under stress.

🏆Accolades and Recognition 

Throughout her illustrious career, Dr. Mazure has received numerous accolades, underscoring her significant contributions to cancer research. She was awarded the prestigious Laureate prize from the Fondation Aventis in 2001 for her innovative research in human health. She was also the recipient of the Madeleine and Jean Schaeverbeke Prize in 2010, awarded by the Fondation de France, recognizing her exceptional work in cancer biology.

🌍 Impact and Influence 

Community Impact

Dr. Mazure’s research has had a profound impact on both the scientific community and clinical applications. Her discoveries related to cancer cell metabolism and resistance to cell death have opened new avenues for therapeutic interventions targeting the metabolic pathways that tumors exploit for survival. Her work has influenced cancer therapies, particularly those aimed at overcoming resistance to chemotherapy and improving the efficacy of existing treatments.

🔮Legacy and Future Contributions 

As Dr. Mazure continues to lead her research team at C3M, her future contributions are poised to shape the next generation of cancer therapies. Her current focus on the interplay between cancer metabolism and the immune system, as well as her ongoing efforts to understand the role of hypoxia in cancer progression, will likely lead to the development of more targeted and personalized cancer treatments.

Conclusion

Nathalie Mazure’s career has been defined by a relentless pursuit of scientific knowledge, a commitment to improving cancer treatments, and a strong dedication to fostering international collaborations. Through her research, leadership, and mentoring, she has made a significant impact on the field of cancer biology and beyond. As she continues to push the boundaries of scientific discovery, her legacy will undoubtedly inspire future generations of researchers and clinicians dedicated to improving human health

📚Publications

YAP1 modulation of primary cilia‐mediated ciliogenesis in 2D and 3D prostate cancer models

Authors: Yingbo Guo; Mathilde Dupart; Marie Irondelle; Pascal Peraldi; Frederic Bost; Nathalie M. Mazure
Journals: FEBS Letters

CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism

Authors: Vincent Rondeau; Maria Kalogeraki; Lilian Roland; Zeina Abou Nader; Vanessa Gourhand; Amélie Bonaud; Julia Lemos; Mélanie Khamyath; Clémentine Moulin; Bérénice Schell et al.
Journals: Science Signaling

Vitiligo auto‐immune response upon oxidative stress‐related mitochondrial DNA release opens up new therapeutic strategies

Authors: Ana Sant’Anna-Silva; Thomas Botton; Andrea Rossi; Jochen Dobner; Hanene Bzioueche; Nguyen Thach; Lauriane Blot; Sophie Pagnotta; Konrad Kleszczynski; Kerstin Steinbrink et al.
Journals: Clinical and Translational Medicine

Yu Hong Li | Gastrointestinal Cancer | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Yu Hong Li  – Gastrointestinal Cancer – Best Researcher Award

Sun yat-sen University | China

      Profile

Scopus

Orcid

📍Current Position

Professor Yuhong Li holds dual roles as a Professor and Chief Physician at the prestigious Sun Yat-sen University Cancer Center. In her current capacity, she leads clinical teams, contributes to innovative research, and mentors the next generation of medical professionals. Her position underscores her influence in medical oncology and her commitment to enhancing cancer care globally.

 

📝Publication Achievements

Professor Li’s contributions to medical literature are both prolific and impactful, featuring studies that drive advancements in oncology: Her co-authored paper on capecitabine maintenance therapy for metastatic colorectal cancer provided significant insights into treatment optimization (Ann of Oncol, 2016). She has explored tumor resistance mechanisms via circulating tumor DNA monitoring, furthering the understanding of colorectal cancer progression (Drug Resist Updat, 2022). Her 2024 TRICE trial publication revolutionized conversion therapy approaches for colorectal liver metastases (Plos Medicine, 2024). Other key studies include innovations in adjuvant chemotherapy efficacy (Theranostics, 2021) and insights into resistance to targeted therapies (Clin Cancer Res, 2011).

 

🔍Ongoing Research

Professor Li’s current focus is on developing personalized treatment strategies for colorectal cancer liver metastases. By integrating clinical trials with translational research, she aims to bridge the gap between laboratory discoveries and patient care. Her dynamic use of circulating tumor DNA to monitor therapeutic resistance showcases her innovative methodologies.

 

🔬 Research Interests

Her research interests span: Gastrointestinal tumors including colorectal, pancreatic, and bile duct cancers. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The interplay of immune checkpoint inhibitors with genetic mutations in liver metastases.

 

🎓Academic Background

Bachelor’s Degree in Clinical Medicine, Bengbu Medical College (1986–1991). Master’s Degree in Oncology, Sun Yat-sen University (1994–1997). Doctorate in Oncology, Sun Yat-sen University (2000–2003). Her robust academic journey laid the foundation for her expertise in oncology.

 

🏆Scholarships and Awards

While specific accolades are not listed, her academic progression and professional trajectory reflect a history of recognition for excellence.

 

🧬Bioinformatics 

Professor Li integrates bioinformatics in her research, particularly for: Dynamic monitoring of circulating tumor DNA, enabling real-time insights into tumor response. Analyzing genetic resistance patterns to improve therapeutic accuracy.

 

🌐Professional Associations 

Professor Li is likely affiliated with leading oncology and gastroenterology societies, enhancing her collaborative impact.

 

 📚Training & Workshops 

She has completed multiple Good Clinical Practice (GCP) certifications (2001, 2006, 2007), demonstrating her dedication to ethical and high-standard clinical trials.

 

🎤Oral Presentations and🗣️Thought Leadership 

As an esteemed researcher, Professor Li frequently presents at national and international forums, sharing her findings and contributing to global oncology discussions.

 

🧑‍🔬Tasks Completed as a Researcher 

Design and execution of clinical trials for gastrointestinal cancer therapies. Translational research bridging laboratory innovations to clinical applications. Publication of high-impact papers, influencing clinical practices worldwide.

 

🚀Success Factors 

Her success is attributed to: Dedication to patient care and research excellence. The ability to collaborate across disciplines to innovate solutions. A focus on mentorship and education, ensuring sustainability in medical advancements.

 

🧪Publications & Laboratory Experience

With a portfolio of groundbreaking publications, Professor Li’s laboratory experience focuses on experimental designs that translate into actionable clinical strategies.

 

🔍 Conclusion

Professor Yuhong Li’s contributions to medical oncology position her as a global leader in cancer research. Her unwavering commitment to personalized care, innovative methodologies, and clinical excellence makes her an ideal candidate for any Best Researcher Award. Her efforts not only push the boundaries of science but also bring tangible improvements to patients’ lives worldwide.

📚Publications

Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

           Author: Wang, F., Wang, Y., Ren, C., … Li, S., Guo, G.

          Journal: Pancreatology

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

           Author: Li, Z.-J., Pat Fong, W., Zhang, D.-S., … Li, Y.-H., Wang, D.-S.

          Journal: npj Precision Oncology

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

           Author: Wang, F., Jin, Y., Wang, M., … Zhao, Q., Xu, R.-H.

           Journal: Nature Medicine

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/ BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

           Author: Wang, D.-S., Ren, C., Li, S.-S., … Xu, R.-H., Li, Y.-H.

          Journal: PLoS Medicine

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

           Author: Sun, Y.-T., Lu, S.-X., Lai, M.-Y., … Yang, D.-J., Qiu, M.-Z.

          Journal: Cancer Immunology, Immunotherapy